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Background: Diffuse large B-cell lymphoma sometimes involves the endocrine organs, but involvement of both the
pituitary and adrenal glands is extremely rare. Involvement of these structures can lead to hypopituitarism and adrenal
insufficiency, and subsequent recovery of their function is rarely seen. The present report describes an extremely rare
case of pituitary and adrenal diffuse large B-cell lymphoma presenting with hypopituitarism and adrenal insufficiency
with subsequent recovery of pituitary and adrenal function after successful treatment of the lymphoma.
Case presentation: A 63-year-old Japanese man was referred to our hospital due to miosis, ptosis, hypohidrosis of his
left face, polydipsia and polyuria. 18F-fluorodeoxy glucose positron emission tomography / computed tomography
revealed hotspots in the pituitary gland, bilateral adrenal glands and the apex of his left lung. Surgical biopsy from the
pituitary lesion confirmed the diagnosis of diffuse large B-cell lymphoma, with lymphoma cells replacing normal pituitary
tissue. Endocrine function tests revealed adrenal insufficiency and panhypopituitarism, including a possible affection of
the posterior pituitary. Hormone replacement therapy with desmopressin and hydrocortisone was started.
Chemotherapy consisted of six courses of R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin and
prednisolone) and two courses of high-dose methotrexate followed by autologous hematopoietic stem cell
transplantation. Subsequently, his pituitary and bilateral adrenal lesions resolved, and serial endocrine function tests
showed gradual improvement in pituitary and adrenal function.
Conclusions: The present report describes an extremely rare case of diffuse large B-cell lymphoma with involvement of
both the pituitary and bilateral adrenal glands. R-CHOP and high-dose methotrexate therapy followed by autologous
hematopoietic stem cell transplantation was quite effective, and panhypopituitarism and adrenal insufficiency improved
to almost normal values after successful treatment of the lymphoma with chemotherapy.
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Diffuse large B-cell lymphoma (DLBCL) sometimes in-
volves the endocrine organs, but the involvement of both
the adrenal and pituitary glands is extremely rare, both at
the time of initial presentation and late in the disease course
[1,2]. Similar to pituitary adenomas, pituitary lymphomas
may present with symptoms of anterior pituitary hormone
dysfunction. In most cases with pituitary involvement of* Correspondence: mshira@intmed3.med.kyushu-u.ac.jp
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distribution, and reproduction in any mediumlymphoma, hormonal dysfunction is irreversible [3,4]. The
present report describes a rare case of panhypopituitarism
and diabetes insipidus due to the involvement the pituitary
gland and the adrenal glands with lymphoma. However,
pituitary and adrenal function was restored after success-
ful chemotherapy and autologous hematopoietic stem cell
transplantation.Case presentation
A 63-year-old man was referred to our hospital due to
miosis, ptosis, hypohidrosis of his left side, polydipsia andtral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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lesions involving the pituitary gland, the apex of the left
lung (Figure 1A), and the left adrenal gland (Figure 1B).
18F-fluorodeoxy glucose positron emission tomography /
CT (18F-FDG PET/CT) imaging indicated high 18F-FDG
uptake in the pituitary gland, bilateral adrenal glands and
the lesion at the apex of his left lung (Figure 1C-F).
Magnetic resonance imaging (MRI) of the brain revealed
an enhanced suprasellar lesion (φ13 mm) and thickening
of the pituitary stalk (Figure 1G,H). Surgical biopsy of the
pituitary lesion showed that the pituitary gland was almost
completely replaced by large abnormal lymphocytes
(Figure 2A,B), which were positive for B-cell markers
(CD20) (Figure 2C), but negative for T-cell markers (CD3)
(Figure 2D).
Laboratory data on admission are shown in Table 1. Mild
anemia and slight elevation of lactate dehydrogenase were
seen, and soluble interleukin-2 receptor (sIL-2R) levels were
within the normal range. Bone marrow aspiration and cere-
brospinal fluid examination were negative for the presence
of lymphoma cells. Basal levels of growth hormone (GH),
luteinizing hormone (LH), follicle stimulating hormone
(FSH), plasma adrenocorticotropic hormone (ACTH),
serum cortisol, thyroid stimulating hormone (TSH), free
thyroxine (f-T4), testosterone, dehydroepiandrosterone
(DHEA) and aldosterone were low, and endocrine func-
tion tests revealed hypo-responsiveness to stimulation,Figure 1 Imaging analysis. A. Chest computed tomography (CT) shows l
shows a left adrenal lesion (yellow arrow). C, D, E, F. 18F-fluorodeoxy gluco
high uptake in the pituitary gland (C), left lung lesion (D), and bilateral adr
magnetic resonance imaging (MRI). G. Coronal section. H. Sagittal section.
(circled in yellow). I and J. Post-treatment pituitary T1-weighted magnetic r
chemotherapy, pituitary lesion disappeared (circled in red).indicating panhypopituitarism and adrenal insufficiency
(Table 2). As the patient had polydipsia and polyuria
(intake and urine volume approximately 5 liters / 24
hours)) with excessive thirst, and further testing showed
low urinary osmolality and low antidiuretic hormone
compared with serum osmolality (Table 1), the diagnosis
of diabetes insipidus could not be excluded. The overall
condition of the patient did not allow a deprivation test.
Based on these data, the patient was diagnosed with
DLBCL with pituitary and adrenal involvement. Hormone
replacement therapy was initiated with thyroxine (25 μg/
day), desmopressin (5 μg/day), and hydrocortisone (30–40
mg/day). Since his international prognostic index was con-
sistent with poor prognosis, we performed six cycles of
chemotherapy with rituximab (375 mg/m2, day 1), cyclo-
phosphamide (750 mg/m2, day 2), vincristine (1.4 mg/m2,
max 2 mg/body, day 2), doxorubicin (50 mg/m2, day 2) and
prednisolone (100 mg/body/day, day 1–5) (R-CHOP)
followed by planned autologous hematopoietic stem cell
transplantation (auto-HSCT). To prevent infiltration of
DLBCL into the central nervous system, two cycles of
intravenous high-dose methotrexate (3.5 g/m2/day, day 1)
therapy (HD-MTX) and two cycles of intrathecal injection
of MTX (15 mg/body), cytarabine (40 mg/body), and dexa-
methasone (3.3 mg/body) were performed (Figure 3).
Following administration of these chemotherapies, the pitu-
itary and bilateral adrenal lesions disappeared on MRI, CT,esion at the apex of the left lung (yellow arrow). B. Abdominal CT
se positron emission tomography (18F-FDG PET) / CT. Arrows indicate
enal glands (E and F). G and H. Pre-treatment pituitary T1-weighted
Suprasellar lesion (φ13 mm) and thickening of the pituitary stalk
esonance imaging (MRI). I. Coronal section. J. Sagittal section. After
Figure 2 Histology of the pituitary lesion. A. Hematoxylin-Eosin (HE) stain (×100). The pituitary gland is completely replaced by abnormal
lymphocytes. B. HE stain (×400). The sections show diffuse proliferation of large-sized abnormal lymphoid cells. C. CD20 immunostaining (×400).
These atypical cells are positive for CD20. D. CD3 immunostaining (×400). These atypical cells are negative for CD3.






WBC 5960 /μl TP 6.1 g/dl sIL-2R 702.3 (206–713)* U/ml SG 1.002
Neut 53.4 % Alb 3.8 g/dl CYFRA 2 (< 3.5)* ng/ml Osmolality 178 mOsm/kg/H2O
Lym 36.9 % BUN 14 mg/dl ProGRP 49.9 (< 81)* pg/ml Na 18 mmol/l
Mo 8.2 % Cre 0.88 mg/dl CEA 1.3 (< 5.0)* ng/ml Volume 5475 ml/day
Eo 1.2 % UA 3.9 mg/dl
Ba 0.3 % T-bil 0.8 mg/dl Endocrinology (basal hormone levels)
RBC 363×104 /μl D-bil 0.4 mg/dl GH 0.4 (< 2.47)* ng/ml
Hb 11.9 g/dl AST 13 U/l PRL 20.9 (4.29-13.69)* ng/ml
Plt 18.4×104 /μl ALT 16 U/l LH 0.2 (0.79-5.72)* mU/ml
ALP 175 U/l FSH 1 (2.00-8.30)* mU/ml
Coagulation γ-GTP 20 U/l ACTH 2 (7.2-63.3)* pg/ml
PT % 111 % LDH 230 U/l Cortisol 2.4 (4.0-18.3)* mg/dl
APTT 29.9 sec Na 139 mmol/l IGF-1 105 (75–226)* ng/ml
Fib 255 mg/dl K 3.8 mmol/l TSH 0.04 (0.5-5.0)* μU/ml
D-Dimer 0.9 μg/ml Cl 100 mmol/l f-T4 0.86 (0.90-1.70)* ng/dl
Ca 8.7 mg/dl ADH 0.5 (0.3-3.5)* pg/ml
Infection CK 19 U/l Testosterone < 0.02 (1.31-8.71)* ng/ml
QFT (+) CRP 0.06 mg/dl DHEA-EIA 7 (24–244)* μg/dl
Osmolality 288 mOsm/kg/H2O Aldosterone 11.4 (35.7-240)* pg/ml




Pathologic parameters were underlined.
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Table 2 Results of endocrine function tests on admission
CRH/TRH/LHRH loading test
Min. 0 15 30 60 90 120
LH (mU/ml) <0.2 <0.2 <0.2 <0.2 <0.2 <0.2
FSH (mU/ml) <1.0 1.1 1.8 2.5 3.1 3.5
PRL (ng/ml) 20.9 39.8 38.7 29.8 26.4 25.9
TSH (μU/ml) 0.04 0.12 0.17 0.2 0.21 0.19
ACTH (pg/ml) <2.0 5.8 8.9 7.8 5.7 4.8
Cortisol (μg/ml) 2.4 2.3 2.2 2 1.8 4.8
GHRP-2 loading test
Min. 0 15 30 45 60
GH (ng/ml) 0.4 2.3 2.5 1.7 1.1
ACTH loading test
Min. 0 30 60 120
Cortisol (μg/ml) 2 3.8 4.6 5
Figure 3 Clinical course. Hormone replacement therapy for pituitary and
Line graphs show the transition of soluble interleukin-2 receptor (sIL-2R) an
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on CT scan, no significant 18F-FDG uptake was shown in
PET/CT, so the lung lesion was considered as not viable.
The level of sIL-2R had been within reference range during
the chemotherapy (Figure 3).
The results of endocrine function tests before and
after chemotherapy are shown in Figure 4. Panels A-F
show the results of corticotropin-releasing hormone
(CRH), thyrotropin-releasing hormone (TRH), and the
LH-releasing hormone (LHRH) loading test. These 3
loading tests were combined and performed at the
same time. Secretion of LH, FSH, TSH, and ACTH
were severely suppressed at the time of diagnosis, but
dramatically improved after the completion of chemo-
therapy (Figure 4A,B,D,E), and the basal ACTH level
improved to the upper limit of the reference range,
according to the reduction of hydrocortisone.
Although the basal and stimulated values of PRL were
within the reference range before treatment, a decrease in
the basal level and an increase in the peak level were found
after successful treatment of the lymphoma, suggesting
resolution of hypothalamic compression (Figure 4C). Thisadrenal insufficiency, and chemotherapy for DLBCL were performed.
d basal levels of ACTH.
Figure 4 The results of endocrine function tests before and after chemotherapy. (A, B) The response of LH (A) and FSH (B) to LHRH
loading test. (C, D) The response of PRL (C) and TSH (D) to TRH loading test. (E, F) The response of ACTH (E) and cortisol (F) to CRH loading test.
(G) The response of cortisol to ACTH loading test. (H) The response of GH to GHRP-2 loading test. Dashed lines show the data of each hormone
at diagnosis, and solid lines show those after chemotherapy.
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disappearance of the suprasellar region projecting to the
hypothalamus after treatment of the lymphoma (Figure 1I
and J). As shown in Figure 4F and 4G, the impairment of
cortisol secretion was explained by the functional defects
in the pituitary gland. After chemotherapy, improvement
in cortisol secretion indicated recovery from secondary
hypoadrenalism. Considering the involvement of DLBCL
in bilateral adrenal glands, a possibility of primary hypo-
adrenalism cannot be excluded. Nonetheless, the successful
treatments lead to the recovery of adrenal insufficiency.
Figure 4H shows the results of the GH releasing protein-2
(GHRP-2) loading test; the deficit in secretion of GH
persisted after chemotherapy. As the treatment progressed,
the symptoms of diabetes insipidus decreased, and the
desmopressin dose was gradually decreased to 1.25 μg/day,
and then, the requirement of hydrocortisone was alsodecreased to 7.5 mg/day (Figure 3). Under this replacement
regimen, basal hormone levels of cortisol, TSH and f-T4
improved to 15.8 μg/dl, 0.43 μU/ml and 0.94 ng/dl respect-
ively. The basal level of testosterone was not improved
(0.02 ng/ml). The basal level of testosterone was not
improved, so testosterone replacement therapy will be
initiated with the next follow-up visits.
Discussion
The present report describes an extremely rare case of
DLBCL with pituitary and bilateral adrenal involvement.
There are only three such cases reported in the literature
(Table 3), all of which involved elderly males. Two cases
involved DLBCL, while the remaining case involved
diffuse large cell non-Hodgkin’s lymphoma, but immu-
nohistochemical data were not available. Frequent pri-
mary symptoms in those cases were ptosis caused by
Table 3 Summary of case reports with pituitary and adrenal involvement in patients with lymphoma
Age/
gender












Pituitary gland, Bilateral adrenal
glands
No treatment T4, GC Died, 9 weeks [5]
59/M DLBCL Weakness, Ptosis, Mild
Hyponatremia, Headache
Pituitary gland, Bilateral adrenal
glands
R-CHOP, IT MTX T4, GC, T,
Fludro
Alive, 18 months [6]
77/M DLBCL Fever, Hyponatremia, Ptosis Pituitary gland, Bilateral adrenal
glands, Liver, Spleen, Bone
marrow
CHOP, IT MTX GC Died, 12 months
in remission
[1]
63/M DLBCL Polyuria, Polydipsia, Miosis,
Ptosis, Hypohidrosis of his left
side







Alive, 15 months This
report
M male, NHL non-Hodgkin’s lymphoma, DLBCL diffuse large B-cell lymphoma, CHOP cyclophosphamide, doxorubicin, vincristine, prednisolone, IT intrathecal
injection, MTX methotrexate, R-CHOP rituximab combined with CHOP.
HD high dose, auto-HSCT autologous hematopoietic stem cell transplantation, T4 thyroxin, GC glucocorticoid, T testosterone, Desmo desmopressin, Fludro
fludrocortisone.
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tremia, and weakness due to corticosteroid insufficiency.
Other involved sites of the lymphoma that varied with
the specific case. Among primary symptoms in our case,
miosis, ptosis, and hypohidrosis of his left face were
similar to a pancoast tumor. Since the lesion in the apex
of the left lung persisted on CT, but its 18F-FDG uptake in
18F-FDG PET/CT disappeared after intensive chemotherapy,
we consider that this lesion was also a nidus of malignant
lymphoma. Furthermore, polydipsia and polyuria suggested
the existence of pituitary lesion, and several imaging exami-
nations, especially 18F-FDG PET/CT, were useful to evaluate
the localization of the lesions. For histological confirmation,
we examined a pituitary lesion by Hardy’s operation, which
was considered to be the operative strategy associated with
the lowest burden on the patient. Finally, a successful diag-
nosis of DLBCL was made, which is the most common
diagnosis among those with pituitary and adrenal lymph-
omas (Table 3).
Although histological examination was performed only
in the pituitary lesion, the efficacy of chemotherapy in
terms of resolving the adrenal and lung lesions suggests
that those lesions were also malignant lymphoma.
Except for one patient who did not receive chemo-
therapy, CHOP or R-CHOP chemotherapy led to
sustained remission (Table 3). To address concerns re-
garding the risk of infiltration of lymphoma cells into
the cerebrospinal fluid, intrathecal injection of MTX
was performed in three cases, and no central nervous
system relapse was reported. In the present case, autolo-
gous peripheral stem cell transplantation was performed
in addition to chemotherapy. Non-Hodgkin’s lymphoma
can be classified into four different groups according to
international prognostic index, and worse prognosis is
associated with the high-intermediate- and high-risk
groups [7]. Auto-HSCT has been tried to improve sur-
vival of the high-risk cases.In the present case, pituitary and adrenal function was
severely impaired at the time of initial diagnosis. However,
as the lesions reduced in response to chemotherapy, pituit-
ary and adrenal function gradually improved, allowing a re-
duction in the dose of hormone replacement therapy.
Some case reports of pituitary lymphoma have described
the restoration of basal hormone levels after successful
chemotherapy [8,9]; the precise mechanism of recovery in
those cases was not clear, but small unaffected tissues
might compensate for the pituitary and adrenal insuffi-
ciency. To avoid excess hormonal replacement, follow-up
evaluation of endocrine function during and after chemo-
therapy is highly recommended.Conclusion
In conclusion, the present study described an extremely
rare case of malignant lymphoma with involvement of the
pituitary and bilateral adrenal glands. Combined therapy
with CHOP and HD-MTX followed by auto-HSCT was
quite effective, and panhypopituitarism and adrenal insuffi-
ciency improved to almost normal values after treatment
of the lymphoma with chemotherapy. Although pituitary
and adrenal lymphomas are rare, it is important to diag-
nose lymphomatous infiltration to those structures in the
early stage of the disease, because pituitary and adrenal
dysfunction might be reversible. Careful endocrinological
follow up is also needed to assure appropriate adjustments
in dosages of hormone replacement therapy in patients
who might have changes in endocrine function for success-
ful treatment of the invading neoplasm.Consent
Written informed consent was obtained from the patient
for publication of this Case report and any accompanying
images. A copy of the written consent is available for review
by the Editor of this journal.
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